Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 25, 2010 Brian Orelli	Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs.
Chemistry World June 10, 2013 Phillip Broadwith	AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
The Motley Fool February 10, 2011 Brian Orelli	Breathe Easier, Join the Competition Novartis' strategy is a good one.
The Motley Fool August 31, 2007 Brian Orelli	Guidelines to Stop the Wheezing Investors, new asthma guidelines will affect some drug makers. The FDA isn't the only organization that affects how well drugs do in the marketplace.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
The Motley Fool May 22, 2009 Brian Orelli	Novartis Breathes Easier Novartis' investors can breathe a little easier. The company's new treatment for chronic obstructive pulmonary disease -- a.k.a. "smoker's lung" -- passed its three phase 3 trials without so much as a cough.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool September 7, 2006 Brian Lawler	SkyePharma Makes a Deal The pharmaceutical sells European rights to a promising asthma drug. With approval not guaranteed, and a cutthroat market for asthma drugs, this deal looks pretty good for Skye overall.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
Pharmaceutical Executive December 1, 2008 Ron Feemster	The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond.
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool June 22, 2007 Brian Lawler	Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note.
The Motley Fool June 26, 2009 Brian Orelli	Novartis Leads the Pack Biosimilars come to Japan; will the U.S. be next? In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
Pharmaceutical Executive April 1, 2011	Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition.
The Motley Fool February 19, 2010 Brian Orelli	Breathe Deep. It Might Not Be That Bad. The FDA strikes down asthma drugs, but will doctors buy in?
The Motley Fool December 1, 2005 Jack Uldrich	How High Is SkyePharma? SkyePharma's technology can create not only more and better new drugs but also reformulate old ones. The company's recent run up to $9 per share still has some legs.
Chemistry World September 10, 2014 Emma Stoye	Cipla targets asthma market with Advair copy Indian pharma company Cipla has begun selling a generic version of GlaxoSmithKline's combination asthma treatment Advair (fluticasone/salmeterol) in Germany and Sweden.
Pharmaceutical Executive May 1, 2011 Cacciotti & Clinton	12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies.
Chemistry World July 31, 2014 Phillip Broadwith	AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments.
The Motley Fool August 28, 2007 Brian Orelli	Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note.
The Motley Fool April 4, 2007 Brian Lawler	Novartis Gets Nicked Novartis pulls one of its top-selling drugs from the market. Investors should come to expect drug delays or similar issues popping up from time to time when doing their analysis of large pharmas.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
American Family Physician January 1, 2007 Scow et al.	Leukotriene Inhibitors in the Treatment of Allergy and Asthma Approximately one third of all prescriptions for maintenance therapy in patients with persistent asthma are for leukotriene inhibitors; however, evidence of their effectiveness compared with other treatments is mixed.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool April 8, 2008 Brian Lawler	FDA Approvals ... Increase? So far in 2008, the agency has given more drugs a thumbs-up than this time in 2007. Take a look at which companies received approvals.
The Motley Fool November 2, 2011 Prabhat Sakya	AstraZeneca vs. GlaxoSmithKline If you could only invest in one of these companies, which would it be?
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool July 18, 2005 Karl Thiel	Stocks That Make You Breathe Easier Allergies and asthma are big markets that several firms aim to tackle. Investors, take note.
The Motley Fool May 16, 2007 Mike Havrilla	Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc.
Pharmaceutical Executive November 1, 2011 Josef Bossart	Pharma Revolution Recalibrated Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
The Motley Fool June 21, 2011 Frank Vinluan	GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV.
American Family Physician September 15, 2004 Matthew Mintz	Asthma Update Part II. Medical Management An evidence-based approach was used to examine several key issues on appropriate medical therapy for patients with asthma. The updated guidelines clarify these issues and should alter the way physicians prescribe asthma medications.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
American Journal of Nursing March 2012 Corbridge et al.	An Evidence-Based Approach to COPD: Part 1 This article, the first in a two-part series on COPD, outlines current guidelines and other evidence-based recommendations on diagnosing and managing stable COPD in the outpatient setting.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
Nurse Practitioner May 2011 Chris Garvey	Best Practices in Chronic Obstructive Pulmonary Disease Chronic obstructive pulmonary disease is a common, preventable, treatable, and often progressive disorder characterized by airflow limitation that is not fully reversible.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool December 31, 2007 Brian Lawler	Does Leadership Count at the FDA? Let's take a look at how drug approval rates have fared under different FDA commissioners.
Pharmaceutical Executive May 1, 2006 Jill Wechsler	Washington Report: Opportunity Knocks FDA has finally released its long-awaited list of research opportunities for the Critical Path initiative. Now comes the hard part, as companies learn how to collaborate on projects that will benefit pharma as a whole.
American Family Physician April 1, 2001 James P. Kemp & Judith A. Kemp	Management of Asthma in Children The prevalence of asthma in children has increased 160 percent since 1980, and the disease currently affects nearly 5 million children in the United States...
Pharmaceutical Executive May 1, 2012	Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
BusinessWeek October 4, 2004 Kerry Capell	Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving.
The Motley Fool November 30, 2009 Brian Orelli	The FDA Moves the Goalposts The FDA sends a complete response letter to Theravance about its antibiotic Vibativ, which it's trying to get approved for treating patients with nosocomial pneumonia.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.